Century Therapeutics (IPSC) Cash from Financing Activities (2020 - 2026)

Century Therapeutics (IPSC) has 7 years of Cash from Financing Activities data on file, last reported at $126.6 million in Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 105419.17% year-over-year to $126.6 million in Q1 2026; TTM through Mar 2026 was $126.7 million, a 124.25% increase from a year earlier, with the FY2025 full-year figure at $173000.0, down 99.77% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $126.6 million, up from $53000.0 in the prior quarter.
• Over the last five years, Cash from Financing Activities for IPSC reached as high as $126.6 million in Q1 2026 and fell as low as -$10.1 million in Q2 2023.
• Historically, Cash from Financing Activities has averaged $14.6 million across 5 years, with a median of $137000.0 in 2022.
• Across the five-year window, Cash from Financing Activities slumped 21177.08% in 2023 and surged 105419.17% in 2026, its largest moves.
• Year by year, Cash from Financing Activities stood at $95000.0 in 2022, then slumped by 474.74% to -$356000.0 in 2023, then sank by 69.1% to -$602000.0 in 2024, then surged by 108.8% to $53000.0 in 2025, then surged by 238811.32% to $126.6 million in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $126.6 million in Q1 2026, $53000.0 in Q4 2025, and $120000.0 in Q1 2025.